BioSpace News Archive

Increase in number of patients living with various dental and related health issues is stimulating the sales avenues in the global needle recapping market.

Rapid prototyping (RP) is one of the applications of rapid manufacturing and a type of computer-aided technology that is capable of making physical objects directly from three-dimensional (3D) computer data by adding a layer-upon-layer

Biophytis SA announces the recommendation by the Data Monitoring Committee to continue patient recruitment into part 2 of the COVA study with the protocol unmodified after review of safety data.

Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis, as measured by EASI, in Eli Lilly and Company’s ADvocate 1 and ADvocate 2 Phase 3 clinical trials.

Medivir AB announced that Medivir AB together with the originators of remetinostat, and TetraLogic Pharmaceuticals Corporation and The Leukemia & Lymphoma Society have restructured and streamlined the financial obligations for remetinostat, a topical histone deacetylase inhibitor, for the treatment of cutaneous T-cell lymphoma and potentially other types of skin cancers.

Biotage is one of the few companies offering a complete solution and ready to go, off-the-shelf products for the purification of large scale lipids, used in mRNA vaccine development and production.

Senhwa Biosciences, Inc., a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that its novel oral drug, Silmitasertib, has reached the enrollment goals for its Phase 2 investigator initiated trial.

Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal therapeutic solutions announced that the Spanish Medicines and Medical Devices Agency allowed Taffix to be marketed in Spain as of August 13th, lifting its prior restriction on marketing issued on March 12.

Nunzia has the exclusive license to sell the IV BLOOD WARMING SYSTEM that is adaptable to handle many of the procedures that are performed in the medical field for the prevention of hypothermia.

Carrick Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer.